Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 24;12(2):93. doi: 10.3390/pharmaceutics12020093

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Delivery of payload from intravenously administered nanoparticles varies by CNS region and surface modification; these data were previously published [15] and are replicated here for direct comparison to Figure 5. (A) Magnitude of DiR delivered from ctr-NPs (left) or RVG-NPS (right) nanoparticles. Data are scaled to min/max concentration for the entire intravenous data set. (B) Percent targeting change calculated by dividing the concentration of DiR delivered from RVG-NPS nanoparticles by the concentration of DiR delivered from ctr-NPs nanoparticles for each tissue region. Data are scaled to the min/max concentration for the entire intravenous data set such that a value of 0 represents no difference in delivery from a targeted nanoparticle compared to a control nanoparticle.